Eli Lilly's Dual-Action Agent, Mounjaro, Receives Marketing Authorization Approval from the European EMA
Mounjaro Overcomes European Regulatory Hurdles
The European Medicines Agency (EMA) has granted final marketing authorization approval for Mounjaro (tirzepatide), Eli Lilly's type 2 diabetes and obesity treatment. This approval signifies Eli Lilly's establishment in Europe, a key territory, within the global metabolic disease market, which has become a major trend. The demonstrated efficacy and safety in the SURPASS Phase 3 trial served as the driving force behind passing the stringent criteria of European regulatory authorities. With this approval, European patients will officially have access to a treatment option that represents an advancement beyond existing single-action agents.
Innovation of GIP and GLP-1 Dual Action
Mounjaro is the first dual-action agent that simultaneously acts on the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Unlike existing treatments that focus solely on the GLP-1 target to help regulate blood sugar, Mounjaro uniquely stimulates the GIP receptor, increasing energy expenditure and inhibiting fat accumulation. This innovative mechanism has garnered significant attention in clinical practice, as it maximizes both blood sugar improvement and weight loss in patients. It is considered a paradigm shift in the medical community due to its ability to address the fundamental causes of metabolic diseases in a multifaceted manner.
Fierce Competition with Novo Nordisk
This approval signals Eli Lilly's full-scale counterattack against Novo Nordisk's Ozempic and Wegovy (semaglutide), which dominate the obesity treatment market. In the SURPASS-2 Phase 3 trial, Mounjaro demonstrated overwhelming superiority in both blood sugar reduction (2.3% decrease in HbA1c) and weight loss (12.4% decrease) compared to semaglutide 1mg. As a result, the global GLP-1 market, which is expected to grow at a double-digit rate annually, will see intensified competition between the two major pharmaceutical companies to secure the leading market share in Europe. To gain market dominance, competition between pharmaceutical companies in terms of marketing and expansion of production capacity will accelerate.
Price and Reimbursement Negotiations Will Determine Market Penetration
Although product approval has been completed, securing reimbursement from national health insurance in each European country is essential for translating it into actual sales. The European market is known for its stringent price negotiations and reimbursement criteria, as each country directly manages its healthcare budget. The initial market penetration speed may vary considerably from country to country, depending on the results of price negotiations with health authorities in major countries such as Germany and France. How well Eli Lilly can persuade the price negotiation table of Mounjaro's excellent cost-effectiveness will be a key variable in the initial sales growth.
This European approval is a pivotal milestone that will drive Eli Lilly's market share expansion in the global metabolic disease market, which is projected to grow to a maximum of $200 billion by 2035. Given that the SURPASS-2 Phase 3 trial demonstrated superior blood sugar control and 12.4% weight loss compared to Novo Nordisk's semaglutide, Mounjaro is expected to rapidly absorb physician preference in the short term. In the medium to long term, as the clinical superiority of the dual-action mechanism is proven, it will serve as important academic evidence for researchers conducting subsequent cardiovascular and renal disease expansion studies, and it will stimulate global pharmaceutical companies to develop dual or triple-target pipelines. Investors and industry professionals should use the trend of price negotiations for reimbursement in each European country and the pace of Eli Lilly's global production facility expansion as evaluation criteria for future performance contributions.
Source: EMA (ema)